Market Overview

Free Technical Research Reports on Biotech Stocks -- Versartis, VIVUS, Xenetic Biosciences, and Ardelyx


Free Technical Research Reports on Biotech Stocks -- Versartis, VIVUS, Xenetic Biosciences, and Ardelyx

PR Newswire

NEW YORK, July 30, 2018 /PRNewswire/ -- If you want a free Stock Review on VSAR, VVUS, XBIO, and ARDX sign up now at On Friday, July 27, 2018, the NASDAQ Composite closed the trading session at 7,737.42, down 1.46%; the Dow Jones Industrial Average edged 0.30% lower, to finish at 25,451.06; and the S&P 500 closed at 2,818.82, slightly dropping 0.66%. This Monday, has released technical reports on the following Biotechnology stocks: Versartis Inc. (NASDAQ:VSAR), VIVUS Inc. (NASDAQ:VVUS), Xenetic Biosciences Inc. (NASDAQ:XBIO), and Ardelyx Inc. (NASDAQ:ARDX). All you have to do is sign up today for this free limited time offer by clicking the link below.


USA-based Versartis Inc.'s stock finished Friday's session 5.26% lower at $1.80 with a total trading volume of 120,503 shares. The Company's shares have advanced 16.13% in the previous three months. The stock is trading below its 50-day moving average by 6.52%. Additionally, shares of Versartis, which operates as an endocrine-focused biopharmaceutical company in the US, have a Relative Strength Index (RSI) of 41.67. Get the full research report on VSAR for free by clicking below at:


On Friday, shares in USA-headquartered VIVUS Inc. recorded a trading volume of 280,583 shares. The stock ended the session 3.79% lower at $0.69. The Company's shares have advanced 80.72% in the previous three months and 37.29% on an YTD basis. The stock is trading above its 200-day moving average by 17.42% and. Moreover, shares of VIVUS, which develops and commercializes novel therapeutic products to address unmet medical needs in human health in the US and the European Union, have an RSI of 41.20.

On July 10th, 2018, VIVUS announced positive preliminary results from a Phase-1 clinical study evaluating the pharmacokinetic profile of its VI-0106 in healthy volunteers. The Company is developing VI-0106, a proprietary soft capsule formulation of tacrolimus for the treatment of pulmonary arterial hypertension. Get access to our top-rated research, including the free report on VVUS at:

Xenetic Biosciences

USA-headquartered Xenetic Biosciences Inc.'s shares closed the day 13.35% lower at $2.92. The stock recorded a trading volume of 154,391 shares. The Company's shares have gained 64.04% over the previous three months and 52.20% since the start of the year. The stock is trading above its 200-day moving average by 24.37%. Additionally, shares of Xenetic Biosciences, which focuses on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics, have an RSI of 42.77. Click here to subscribe for a free membership which welcomes you with our report on XBIO at:


Shares in USA-based Ardelyx Inc. finished 9.30% lower at $3.90. The stock recorded a trading volume of 374,151 shares. The Company's shares have advanced 2.63% in the last month. The stock is trading below its 50-day moving average by 8.19%. Furthermore, shares of Ardelyx, which develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the US and Asia/Pacific, have an RSI of 40.07. To get free access to your research report on ARDX, sign up at:

Stock Trader Report:

Stock Trader Report (STR) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. STR has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

STR has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by STR. STR is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


STR, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. STR, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, STR, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither STR nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Phone number: 917-979-2038
Office Address: 22/F. 3 Lockhart Road, Wanchai Hong Kong

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:

SOURCE Stock Trader Report

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at